Toolio Joins Microsoft for Startups Pegasus Program to Accelerate AI-Powered Retail Planning Innovation
NEW YORK — Toolio, a next-generation merchandise planning platform for modern retailers, today announced its participation in the Microsoft for Startups Pegasus Program.
Article content
Toolio has also launched a strategic integration with Microsoft Azure and is now a transactable solution on Azure Marketplace, enabling Microsoft sales teams to directly bring Toolio's innovative solution to customers worldwide.
Article content
Revolutionizing Retail Planning with Toolio
Article content
Toolio is a cloud-native merchandise planning platform that helps retailers make faster, more data-driven decisions. From merchandise financial planning and open-to-buy management to assortment planning and demand forecasting, Toolio provides a single source of truth for retail planning teams.
Article content
Trusted by leading modern brands like Boll & Branch, MeUndies, Magnolia, and Rothy's, Toolio delivers measurable results—saving time, boosting top-line revenue, and improving profitability and cash flow.
Article content
'Retailers are navigating increasing complexity across channels and inventory. Toolio's AI-powered platform delivers intelligent forecasting, merchandise and assortment planning, allocation, and end-to-end analytics, giving retailers the visibility and insights needed to optimize inventory and drive smarter decisions,' said Tom Davis, Partner at Microsoft for Startups. 'Through the Pegasus Program, Toolio can now leverage Microsoft's resources to scale its impact and help retailers operate with greater efficiency and confidence in today's dynamic landscape.'
Article content
Built on Azure: Scalable, Intelligent, and Future-Ready
Article content
Toolio's platform, built on Microsoft Azure with integrations into Dynamics and Power BI, ensures enterprise-grade reliability and speed. Its cloud-based solution offers ease of use, flexibility, connected planning, and rapid time to value through a scalable infrastructure.
Article content
By integrating with ERP systems like Dynamics, Toolio syncs critical data such as sales, inventory, product details, POs, receipts, and transfers in real-time. Once finalized, plans are seamlessly exported back to the ERP for operational execution.
Article content
Retailers benefit from enhanced data accuracy, streamlined operations, and improved decision-making capabilities, leveraging the power of connected planning and real-time insights provided by Power BI.
Article content
The platform also utilizes advanced AI and ML workflows—powering key retail planning functions:
Article content
Demand Forecasting with XGBoost & LightGBM
Clustering stores & products for smarter regional planning
Promo & Markdown Optimization based on price elasticity
AI-generated Business Reviews with OpenAI
Exception Alerts that guide planners to key insights
Article content
Toolio's Future Plans with Microsoft
Article content
As part of the Pegasus program, Toolio is working on migrating large-scale datasets, scaling ML workflows with automated model training, hyperparameter tuning, and model tracking, and enhancing monitoring, resilience, and notifications through Microsoft's observability stack
Article content
Toolio's technical roadmap is closely aligned with Microsoft's enterprise ecosystem—bringing AI-driven planning to the forefront of retail transformation.
Article content
Founded in New York, Toolio is a cloud-based merchandise planning platform helping retailers streamline their end-to-end planning workflows. Built for speed, collaboration, and intelligence, Toolio enables better decisions through data.
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 hours ago
- Globe and Mail
TRB Advisors LP Boosts Stake in Microsoft
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TRB Advisors LP, managed by Heath L. Watkin, recently executed a significant transaction involving Microsoft ((MSFT)). The hedge fund increased its position by 25,000 shares. Spark's Take on MSFT Stock According to Spark, TipRanks' AI Analyst, MSFT is a Outperform. Microsoft's overall stock score is driven by its strong financial performance and positive earnings call sentiment. The company benefits from consistent revenue growth and high profitability, supported by effective cash flow management and a solid balance sheet. Technical indicators show positive momentum, although overbought conditions suggest caution. The high P/E ratio reflects market confidence but also hints at potential overvaluation. Continued strength in cloud and AI services positions Microsoft well for future growth. To see Spark's full report on MSFT stock, click here. More about Microsoft YTD Price Performance: 22.23% Average Trading Volume: 19,731,068 Current Market Cap: $3809.7B Disclaimer & Disclosure Report an Issue
Globe and Mail
a day ago
- Globe and Mail
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency. In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership. With the successful launch of our proprietary AI-driven PredicTcell™ platform, we've significantly enhanced target discovery efficiency. Strategic partnerships with global technology leaders, such as Microsoft and Databricks, have accelerated our progress. Recent patent filings further secure our intellectual property in AI-driven predictive modeling, positioning us at the forefront of innovation. Importantly, Tevogen Bio is well capitalized, having access to necessary funding we may require to fully execute our current growth strategy, including the accelerated development of While the sector faces significant challenges, our company continues to grow, underscoring the foundational strength of our company. We deeply appreciate your continued support as we work toward our vision of transforming healthcare through democratizing access. It feels good to be part of this growth story and am grateful to my colleagues at Tevogen for their exceptional expertise, dedication, and, above all, their compassion for others. Sincerely, Ryan Saadi, MD, MPH Founder and CEO, Tevogen Bio Recent Announcements Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts
CTV News
a day ago
- CTV News
Amazon tumbles after cloud computing growth disappoints investors
shares fell seven per cent on Friday as the tech giant's results fanned investor fears its cloud unit was falling behind Microsoft and Alphabet in the artificial intelligence race. shares fell seven per cent on Friday as the tech giant's results fanned investor fears its cloud unit was falling behind Microsoft and Alphabet in the artificial intelligence race. Amazon Web Services, long the cloud-computing market leader, edged past Wall Street estimates for June-quarter revenue on Thursday with a 17.5 per cent increase, but it widely lagged the 39 per cent growth seen at Microsoft Azure and Google Cloud's 32 per cent gain. That disappointing growth came even as Amazon shelled out US$31.4 billion in capital expenditure, more than rivals, and suggested it would spend a more-than-estimated $118 billion for the year. Google and Microsoft also pledged higher spending, but were rewarded from investors on signs AI was already becoming a major growth driver across their businesses, justifying the bill. The companies have been spending billions of dollars on datacenters and cutting-edge chips that they say are necessary to overcome supply constraints hampering their efforts to capitalize on soaring demand for AI services. 'The spotlight was firmly on AWS and it didn't quite shine as brightly as expected,' said Matt Britzman, senior equity analyst at Hargreaves Lansdown. 'While Microsoft and Alphabet have already shown strong momentum in cloud growth, AWS wasn't the knockout many wanted to see.' Growing expenses have also started to take a bite out of AWS's margins, the business that has long been Amazon's profit engine, accounting for about 60 per cent of its operating income. AWS margins contracted to 32.9 per cent during the quarter, their lowest level since the final quarter of 2023, and Amazon also issued a current-quarter total operating income forecast that was lower than market estimates. CEO Andy Jassy told analysts on a post-earnings call that it was still 'very early days' in the AI race and that Amazon's massive cloud business, much larger than rivals, was primed to perform well once the AI capacity constraints start to ease. The stock, now down 1.5 per cent for the year, was at $216.2 in late morning trading. The drop was set to erase around $170 billion from Amazon's market value, if the losses hold. The company still trades at a relatively high premium, with a 12-month forward price-to-earnings ratio of 33.87, compared with Microsoft's 34.19 and Alphabet's 18.64, according to data compiled by LSEG. Retail resilience At least 30 analysts raised their price targets on the stock, while three lowered, giving it a median view of $260. Some of that analyst confidence comes from the strong performance of Amazon's retail business, which has remained resilient in the face of Trump administration tariffs that have hobbled many retailers and their supply chains. Amazon has yet to see a drop in demand or a notable rise in prices in the first half of the year, Jassy said, as its online store sales jumped a better-than-expected 11 per cent in the second quarter. Manufacturers and suppliers have shouldered most of the tariff impact so far, analysts said, but noted that much of the inventory Amazon sold in the quarter arrived in the preceding three-month period. 'If Amazon's retail business was a standalone entity, it would be trading dramatically higher following the near-perfect results,' said Michael Morton, analyst at MoffettNathanson. 'Unfortunately, as we all know, the success of the retail business is not what's going to matter in the near term for Amazon's stock price.' (Reporting by Aditya Soni and Kanchana Chakravarty in Bengaluru and Amanda Cooper in London; Editing by Alun John and Shilpi Majumdar)
